Arthneeti
Latest: Neuland Laboratories Ltd Q1 FY27 results →All Q1 FY26 results →
NL

Neuland Laboratories Ltd

Q1 FY26Pharmaceuticals & Biotechnology

Neuland Laboratories Q1 FY26 earnings call: Revenue & Margins

Q1 FY26 earnings call: what management said on revenue, margins and capex.

Price₹23,301
Market cap₹25.6K Cr
P/E51.4
Updated23 Aug 2026
Read3 min read

The short version

Neuland expects strong growth in sales/revenue for FY26, building on the FY24 base. Management expects strong revenue growth in FY26 and beyond, driven by commercial CMS projects, new molecule commercializations, and peptide segment expansion.

From Neuland Laboratories Ltd's Q1 FY26 earnings-call transcript · updated 23 Aug 2026.

Revenue & Sales Performance

  • Neuland expects strong growth in sales/revenue for FY26, building on the FY24 base.
  • Management calls for a "healthy" to "strong" growth but refrains from specific numerical guidance.
  • The company anticipates a 20% CAGR over a 3-5 year horizon as a reasonable benchmark.
  • Growth drivers include commercial molecules scaling up, new business from existing and new customers, and commercialization of additional CMS molecules.
  • Expansion in peptide and specialty APIs is also expected to contribute significantly.
  • Capacity expansions (such as Unit 3 production block) are expected to support growth in the latter half of FY26.

2 more points from Neuland Laboratories Ltd's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Neuland Laboratories Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

  • CAPEX for FY26 is around Rs. 250 crores.
  • Approximately 60% of this CAPEX is for growth, 40% for maintenance.
  • Investments are being made in expanding capacity, including a new production block in Unit 3 (expected to be operational by August/September).
  • Expansion of Unit 1 is underway, involving acquisition of additional land to enable faster capacity addition compared to Greenfield projects.
  • Peptide facility being built on acquired land next to Unit 1, expected to be completed in the next financial year.

2 more points from Neuland Laboratories Ltd's call on capex

Create a free account to keep reading this call

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

Guidance-ranked
1KRM Ayurveda
Rev 1Mar 1
2Accretion Pha.
Rev 1Mar 2
3
Rev 1Mar 3
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Neuland Laboratories Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

  • Saharsh Davuluri acknowledged the importance of attending to the orderbook.
  • There is mention of a healthy customer pipeline providing good visibility for future revenue.
  • Growth is expected to pick up in the latter half of FY26 with the commercialization of the Unit 3 production block.
  • New business from both existing and new customers is showing significant momentum, expected to realize over FY26 and FY27.

2 more points from Neuland Laboratories Ltd's call on order book

Create a free account to keep reading this call

Neuland Laboratories Ltd — Quarterly revenue & net profit

Revenue Net profit
Dec 2024Q3 FY25
Mar 2025Q4 FY25
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26

Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹776 Cr, net profit ₹213 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Continue your research

What Neuland Laboratories Ltd's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

  • RPG LifeScience. (Q1 FY26)

    168.9 crores vs Rs. Key concall takeaways from RPG Life Sciences Ltd's Q1 FY26 earnings call — and how it ranks against sector peers.

  • SMS Pharma. (Q1 FY26)

    Q1FY26 revenue from operations: ₹196.05 crore . Key concall takeaways from SMS Pharmaceuticals Ltd's Q1 FY26 earnings call — and how it ranks against sector…

  • Morepen Laboratories Ltd (Q1 FY26)

    Crores)**: . Key concall takeaways from Morepen Laboratories Ltd's Q1 FY26 earnings call — and how it ranks against sector peers.

  • NGL Fine Chem Ltd (Q1 FY26)

    Q1FY26 Revenue from operations: ₹104.19 crores . Key concall takeaways from NGL Fine Chem Ltd's Q1 FY26 earnings call — and how it ranks against sector peers.

Compare:vs Sun Pharma.Inds.vs Divi's Lab.vs Torrent Pharmaceuticals Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Neuland Laboratories Ltd and 15K+ more earnings calls,
for less than your morning chai

a day

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Neuland Laboratories Ltd Q1 FY26 results?

Neuland expects strong growth in sales/revenue for FY26, building on the FY24 base. Management expects strong revenue growth in FY26 and beyond, driven by commercial CMS projects, new molecule commercializations, and peptide segment expansion.

What is Neuland Laboratories Ltd share price analysis?

Neuland Laboratories Ltd currently shows a neutral. The stock trades at a P/E of 51.4 with a market cap of ₹25,603 Cr. Investors should review the full earnings analysis for detailed insights.

Is Neuland Laboratories Ltd planning capital expenditure?

CAPEX for FY26 is around Rs.

Keep Neuland Laboratories Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.